@sumileigh's GLP-1 transformation claims, fact-checked

What did @sumileigh actually say?

Technically? Nothing about GLP-1s. The entire transcript is a lyric from Don McLean's "American Pie": "drove my Chevy to the levee but the levee was dry." That's it. There are no health claims, no dosing advice, no before-and-after narration, no explanation of what changed or how. The video's substance lives entirely in its hashtags and visual framing, not its words.

This is actually a pattern worth paying attention to. Creators in the GLP-1 space increasingly let visuals do the talking while keeping transcripts legally clean. The hashtags #glp1, #beforeandafter, and #transformation do the heavy lifting. Viewers fill in the gaps themselves, which is arguably more persuasive than a direct claim, and harder to fact-check.

Does the science back this up?

There's nothing to verify scientifically because no factual claim was made. But the implied narrative, that GLP-1 receptor agonists produce dramatic physical transformations, is broadly supported by clinical evidence, with significant caveats most TikTok videos skip entirely.

Semaglutide (Wegovy) produced mean weight loss of 14.9% of body weight over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM). Tirzepatide (Zepbound) showed up to 20.9% mean weight loss in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). Those are real, meaningful numbers. What those trials also showed: results vary substantially between individuals, weight regain is common after discontinuation, and side effects, including nausea, vomiting, and potential muscle mass loss, affect a meaningful portion of users. A before-and-after photo with a song lyric underneath doesn't capture any of that complexity.

What did they get wrong (or right)?

There's nothing factually wrong here because nothing factual was stated. That's the uncomfortable part. The video is structured to imply a GLP-1 success story without asserting one, which means it can't be called inaccurate in any direct sense.

What it gets right by omission: it doesn't make dangerous dosing claims, doesn't compare compounded semaglutide to brand-name products, and doesn't promise a cure for anything. In a space full of videos that do all three of those things, that's a low bar, but it clears it.

What it gets wrong by implication: transformation content presented without context systematically overstates typical outcomes. Research on health misinformation on social media, including work by Southwick et al. (2023, JMIR), suggests that visual before-and-after content shapes audience expectations more strongly than verbal disclaimers can correct. Showing only a positive outcome, even silently, is a form of selection bias with real consequences for how viewers assess their own likely results.

What should you actually know?

If you found this video while researching GLP-1 medications, here's what the research actually says. These drugs work for a lot of people, but they are not universally effective, they require ongoing use to maintain results, and they come with a side effect profile that deserves a real conversation with a clinician, not a TikTok scroll.

• Weight regain after stopping semaglutide averaged 11.6 percentage points within one year of discontinuation (Wilding et al., 2022, Diabetes, Obesity and Metabolism).
• Lean mass loss is a documented concern. Studies suggest 25-39% of weight lost on GLP-1 agonists may come from muscle, not fat (Bikou et al., 2024, Current Obesity Reports).
• Not everyone gets a dramatic result. In STEP 1, roughly 14% of participants lost less than 5% of body weight.
• Compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic. Purity, concentration, and sterility standards differ. The FDA has flagged compounded versions explicitly.

A song lyric and a transformation hashtag won't tell you any of this. A clinician will.